Axitinib (AG 013736) is a potent multi-target tyrosine kinase inhibitor (TKI), which inhibits VEGFR1, VEGFR2, VEGFR3, PDGFR?, PDGFR? and c-Kit with IC50 values of 1.2 nM, 0.2 nM, 0.1 nM-0.3 nM, 1.6 nM, 5.0 nM, and 1.7 nM, respectively. [1] In human xenograft tumor models (nude mice), Axitinib (AG 013736) shows consistent antitumor efficacy across various tumor types, which is associated with reduction in vascular angiogenesis and tumor proliferation and increase in tumor apoptosis. [1]Axitinib (AG 013736) resulted in significantly longer progression-free survival compared with sorafenib and has been approved as a second-line therapy of advanced renal cell carcinoma. [2]
Technical information:
Chemical Formula: | C22H18N4OS | |
CAS #: | 319460-85-0 | |
Molecular Weight: | 386.47 | |
Purity: | > 98% | |
Appearance: | White | |
Chemical Name: | N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-benzamide | |
Solubility: | Up to 100 mM in DMSO | |
Synonyms: | Axitinib, AG 013736 |
Shipping Condition: The product is shipped in a glass vial at ambient temperature.Storage condition: For longer shelf life, store solid powder or DMSO solution at -20oC desiccated.
Reference:
1. | Hu-Lowe DD, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008; 14(22):7272-83 Pubmed ID:19010843 |
2. | Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors (FavorAx). clinicaltrials.gov/NCT02700568 |
Other Information:
Product Specification (pdf) MSDS (pdf) Certificate of Analysis is available upon request.
Cellagen的ChamQ SYBR qPCR预混液(无ROX)| Q321产品描述ChamQSYBR®qPCR预混液(Vazyme,#Q321)由香槟Taq DNA聚合酶(Vazyme,#P122)通过抗体修饰的热启动激活技术保护,是专为基于SYBR Green I的定量PCR(qPCR)设计的。ChamQSYBR®qPCR Master Mix的优化缓冲液系统中的独特因素(即促进特异性的Exactor)大大提高了其灵敏度和特异性。该混合物以2倍反应浓度制备,可直接用于鲁棒性低模板qPCR,具有高灵敏度,特异性和可靠性。优点特异性+敏感性的最佳组合。独特的抗体修饰的热启动taq,具有独特的特异性促进因子。Mg2 +和染料的最佳浓度。